References

1. Ramadan K, Gomes B, Pipkin M, Olkiewicz M, Bojko B, Mbadjeu Hondjeu AR, et al. A model to assess acute and delayed lung toxicity of oxaliplatin during in vivo lung perfusion. *J Thorac Cardiovasc Surg*. 2021;161:1626-35.
2. Klopp CT, Alford TC, Bateman J, Berry GN, Winship T. Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. *Ann Surg*. 1950;132:811-32.
3. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. *Ann Surg*. 1958;148:616-32.
4. Minchin RF, Johnston MR, Aiken MA, Boyd MR. Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo. *J Pharmacol Exp Ther*. 1984;229:193-8.
5. Pass HI, Mew DJ, Kranda KC, Temeck BK, Donington JS, Rosenberg SA. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. *Ann Thorac Surg*. 1996;61:1609-17.
6. Burt ME, Liu D, Abolhoda A, Ross HM, Kaneda Y, Jara E, et al. Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial. *Ann Thorac Surg*. 2000;69:1542-9.

See Article page 1626.

Commentary: Perceived versus real threat...and the nuclear option

Jacob A. Klapper, MD

In this manuscript, the group at the University of Toronto has demonstrated how their unparalleled expertise in the field of ex vivo lung perfusion may have benefits beyond lung transplantation.¹ The rigor with which this current study was produced does indeed provide a blueprint for a potential phase I study of isolated lung perfusion for the treatment of colorectal metastases.

Again, it is very hard to argue with their methodology and technique, as this group is widely recognized as the world experts in ex vivo lung perfusion. In addition, it is only natural that they would consider the application of this technology to the field of thoracic oncology, where pulmonary mastectomies are commonly performed for a variety of histologies. Furthermore, the precedent for isolated organ perfusion exists in the treatment of metastatic disease to the liver and limb.^{2,3}

I'll admit on first blush such an approach to pulmonary metastases seems appealing despite the morbidity of the procedure (as it's currently designed) and the real potential for delayed pulmonary toxicity. The question I keep coming

Jacob A. Klapper, MD

CENTRAL MESSAGE

Isolated lung perfusion. It can be done. Should it be done?

back to, however, is who would want or need such an operation? I would surmise that the ideal candidate would be an individual with unilateral lung metastases that are either too numerous, too large, or in unfavorable anatomic locations that standard surgical resection is not possible. This would likely make up a small subset of patients, a group that would be further reduced in size by fact that many with lung disease would also have other sites of metastatic disease.

Another theoretical point to consider is the perceived threat versus the real threat of lung metastases. In other words, how life-limiting are lung metastases that we would need a procedure like isolated lung perfusion. For instance, most would agree that lung metastases, unlike implants in other organs, ie, bone or brain, are rather indolent lesions that cause no pain and rarely negatively impact pulmonary function. In addition, we have debated for years what, if any, survival benefit is conferred from the conventional removal of these lesions.

In sum, the importance of accurately assessing whether a perceived threat is a real threat is that many times the

From the Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, NC.

Disclosures: Author has nothing to disclose with regard to commercial support.

Received for publication March 26, 2020; revisions received March 26, 2020; accepted for publication March 27, 2020; available ahead of print April 11, 2020.

Address for reprints: Jacob A. Klapper, Division of Cardiothoracic Surgery, DUMC 3954, Durham, NC 27710 (E-mail: Jacob.klapper@duke.edu).

J Thorac Cardiovasc Surg 2021;161:1637-8

0022-5223/\$0.00

Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery

<https://doi.org/10.1016/j.jtcvs.2020.03.087>

decisions made at this juncture can have significant implications. To put this in a real-world context, consider US policy toward nuclear weapons at the dawn of the Cold War. We perceived a real threat from Soviet proliferation. Thus, by the end of 1962, we had 27,000 nuclear warheads. The Soviets? Just 3300.⁴ In the end, we had created an overwhelming stockpile of weapons that we could not consciously use or dispose of—the danger of overestimating a perceived threat. Isolated lung perfusion looks like the ultimate weapon against lung metastases. But is it a procedure that is more likely to cause more harm than good? Certainly, it will eradicate these lesions,

but like the aforementioned weapons, to what end and at what cost?

References

1. Ramadan K, Gomes B, Pipkin M, Olkowitz M, Bojko B, Hondjeu ARM, et al. A model to assess acute and delayed lung toxicity of oxaliplatin during in vivo lung perfusion. *J Thorac Cardiovasc Surg*. 2021;161:1626-35.
2. Alexander R, Libutti S, Pingpank J, Steinberg SM, Bartlett DL, Hulsabeck C, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. *Clin Cancer Res*. 2003;9:6343-9.
3. Cornett W, McCall L, Petersen R, Ross M, Steinberg SM, Bartlett DL, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons oncology group trial Z0020. *J Clin Oncol*. 2006;24:4196-201.
4. Menand L. Nukes of Hazard. *The New Yorker*; 2013.